Alzheimer’s, known mostly for the memory loss and confusion it causes, may be the nation’s third- most deadly killer, according to a study that suggests many more Americans die from the disease than is known.
Biogen Idec Inc., maker of the multiple sclerosis drugs Avonex, Tysabri and Tecfidera, bought rights to Japan’s Eisai Co.’s experimental Alzheimer’s disease medicines as it seeks to add treatments for brain disorders.
Former SAC Capital Advisors LP fund manager Mathew Martoma asked a judge to throw out his conviction in the most lucrative insider-trading scheme ever, saying prosecutors failed to make a case against him.
A block of 5,000 options betting on a 28 percent jump in Forest Laboratories Inc.’s shares that cost $2.55 million to buy last week more than doubled in value to $6 million today after Actavis Plc agreed to buy the drugmaker.
Former SAC Capital Advisors LP fund manager Mathew Martoma was found guilty in the most lucrative insider-trading scheme ever as federal prosecutors racked up a seventh conviction in their six-year probe of the hedge fund and its billionaire founder, Steven A. Cohen.
Former SAC Capital Advisors LP fund manager Mathew Martoma, who was found guilty Feb. 6 in the most lucrative insider-trading scheme ever, is scheduled to be sentenced June 10 and may face as many as 20 years in prison.
The pesticide DDT, banned in the U.S. because of its toxic effects on wildlife and potential to harm human health, may raise the risk for Alzheimer’s disease, according to the first study linking the chemical to the brain- ravaging illness.